PPARG and Alzheimer disease: In light of the difficulties with these PD biomarkers, and the informativeness of alternations in Aβ levels, it is disappointing that plasma Aβ42 and Aβ40 measurements were not incorporated more widely in clinical trials testing the efficacy of PPARγ agonists to delay the onset of dementia due to AD.